OncoLab's Line of Products

Most of OncoLab's Dx4U tests are in vitro diagnostic tests and are CE-IVD marked. Modified versions of the test are available for research applications (RUO marked).

The products con­tain all reagents nec­es­sary to per­form the tests on widespread com­mer­cially avail­able analy­sis platforms.



OncoLab's current main line of products, the Blood-based Biopsy Tests (BBB) enable the mol­e­c­u­lar detec­tion of Cir­cu­lat­ing Tumor Cells (CTC) as a mea­sure of ther­apy effi­cacy and recur­rence of can­cer. The pres­ence, abundance and molecular char­ac­ter­is­tics of CTC are ana­lyzed by immunofluorescence staining and automated image analysis and by quan­tifi­ca­tion of RNA biomarkers spe­cific for each type of cancer. A comprehensive, fast, most accurate, near-patient CTC detection, enumeration and molecular characterization system will be offered. A test for the detection and enumeration of Circulating Endothelial Cells (CEC) allows for investigating the damaging effect of several diseases on the vascular epithelium and its diagnostic impact. Another test detects Circulating Stromal Cells (CSC) which are indicative for endometrial diseases. CSC are a potential diagnostic target.

All Blood-based Biopsy Tests are non-​invasive and rely on novel con­cepts ensur­ing unprece­dented sen­si­tiv­i­tiy and speci­ficity. This has already been demon­strated for breast cancer and ovar­ian cancer. These tests will be pro­vided for breast can­cer, ovar­ian can­cer, endome­trial can­cer, cer­vi­cal can­cer, col­orec­tal can­cer, and lung cancer.

Due to their non-​invasive nature and easy applic­a­bil­ity these blood tests rep­re­sent so-called ‘LIQ­UID BIOP­SIES’ which— unlike tis­sue biop­sies — can the­o­ret­i­cally be per­formed an unlim­ited num­ber of times.


© OncoLab Diagnostics GmbH 2019

OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Str. 2, Bldg. E
2700 Wiener Neustadt